#1 Clinical Trials Search in Europe

Formoterol Fumarate Dihydrate

This article discusses clinical trials investigating the use of Formoterol Fumarate Dihydrate, often in combination with other drugs like Budesonide, for treating asthma and chronic obstructive pulmonary disease (COPD). These studies aim to evaluate the effectiveness, safety, and patient satisfaction of various inhaler formulations containing this medication.

Table of Contents

What is Formoterol Fumarate Dihydrate?

Formoterol fumarate dihydrate is a medication used to treat respiratory conditions. It belongs to a class of drugs called long-acting beta agonists (LABAs). Formoterol works by relaxing and opening the airways in the lungs, making it easier to breathe[1].

What Conditions Does Formoterol Treat?

Formoterol is primarily used to treat two main respiratory conditions:

  • Asthma: A chronic lung condition characterized by inflammation and narrowing of the airways, leading to breathing difficulties[1].
  • Chronic Obstructive Pulmonary Disease (COPD): A group of lung diseases, including chronic bronchitis and emphysema, that cause airflow blockage and breathing-related problems[2].

In some cases, formoterol may also be used in patients with lung cancer or those at risk of developing lung cancer, as part of research studies investigating its effects on gene expression and inflammation[3].

How Does Formoterol Work?

Formoterol works by:

  • Relaxing the muscles around the airways in the lungs, which helps to open them up
  • Reducing inflammation in the airways
  • Providing long-lasting relief from symptoms such as shortness of breath, wheezing, and coughing

These effects can help improve lung function and make breathing easier for patients with asthma or COPD[4].

How is Formoterol Administered?

Formoterol is typically administered through inhalation. There are several types of inhalers that may be used:

  • Metered-dose inhalers (MDIs): These devices deliver a specific amount of medication in aerosol form[1].
  • Dry powder inhalers: These deliver the medication in a dry powder form that is inhaled[5].
  • Digital inhalers: These are advanced devices that can monitor medication use and provide feedback on inhaler technique[6].

The typical dosage is two inhalations twice daily, but this can vary depending on the specific product and your doctor’s instructions[1].

Combination Therapies with Formoterol

Formoterol is often used in combination with other medications to provide more effective treatment for asthma and COPD. Common combinations include:

  • Budesonide/Formoterol: This combination includes an inhaled corticosteroid (budesonide) to reduce inflammation along with formoterol. It’s often sold under brand names like Symbicort[1].
  • Aclidinium Bromide/Formoterol: This combination includes a long-acting muscarinic antagonist (aclidinium bromide) along with formoterol, used primarily for COPD treatment[4].

Current Clinical Research on Formoterol

Ongoing research is exploring various aspects of formoterol use, including:

  • Comparing the effectiveness of generic versions to brand-name products[1]
  • Investigating its effects on oxygen consumption and cardiac function in COPD patients[2]
  • Studying its impact on gene expression and inflammation markers in patients with lung conditions[3]
  • Evaluating new delivery devices and digital health technologies to improve treatment outcomes[6]

Potential Side Effects and Safety Considerations

While formoterol is generally well-tolerated, it can cause side effects in some patients. Common side effects may include:

  • Headache
  • Tremor
  • Rapid heartbeat
  • Nervousness

It’s important to use formoterol exactly as prescribed by your doctor. Overuse of LABAs like formoterol can increase the risk of asthma-related death. Always discuss any concerns or side effects with your healthcare provider[7].

Aspect Details
Main Drug Formoterol Fumarate Dihydrate, often combined with Budesonide
Conditions Studied Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Study Designs Randomized, placebo-controlled, multi-dose, parallel-group, crossover
Primary Outcomes FEV1 measurements, area under the curve (AUC) of FEV1, changes in lung function
Secondary Outcomes Patient satisfaction, quality of life, adverse events, oxygen consumption
Delivery Methods Various inhalers including pMDIs, Turbuhaler, Spiromax
Duration of Studies Ranging from single-dose to 12-week treatments
Patient Populations Adults with asthma or COPD, some studies include adolescents

FAQ

  • What is Formoterol Fumarate Dihydrate? Formoterol Fumarate Dihydrate is a long-acting beta-agonist (LABA) medication used in inhalers to treat asthma and COPD. It helps to relax and open the airways, making breathing easier for patients with these conditions.
  • How is Formoterol Fumarate Dihydrate typically used in clinical trials? In clinical trials, Formoterol Fumarate Dihydrate is often combined with other medications, such as Budesonide (an inhaled corticosteroid). It is typically administered through inhalers or other devices designed for oral inhalation.
  • What are some of the main objectives of these clinical trials? The main objectives include evaluating the effectiveness of the medication in improving lung function, assessing patient satisfaction and ease of use with different inhaler devices, and comparing the test products to existing treatments or placebos.
  • How do researchers measure the effectiveness of these medications in clinical trials? Researchers use various measurements, including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and area under the curve (AUC) of FEV1 over time. They also assess patient-reported outcomes like quality of life and symptom improvement.
  • Are there any potential side effects or safety concerns studied in these trials? Yes, the trials monitor for adverse events and safety concerns. Common areas of focus include changes in heart rate, blood pressure, and potential oral infections. Researchers also assess the overall tolerability of the medication.

Ongoing Clinical Trials on Formoterol Fumarate Dihydrate

  • Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma Not Well Controlled

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Hungary Italy Poland Romania Spain

  • Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Greece Portugal Slovakia

  • Study on the Effects of Budesonide, Glycopyrronium, and Formoterol in Patients Aged 40-80 with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Hungary Poland

  • Study on the Effectiveness and Safety of CHF 5993 Compared to CHF 1535 for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Poland Romania

  • Study on the Effectiveness and Safety of Budesonide and Formoterol Fumarate for Patients with Poorly Controlled Asthma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • Study on the Effects of Budesonide, Glycopyrronium, and Formoterol on Exercise in Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

  • Study on the Effectiveness of Beclometasone, Glycopyrronium, and Formoterol in COPD Patients with Asthma Characteristics

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Greece Hungary Italy +5

  • Study Comparing Trelegy with LABA-LAMA Drug Combination for Improving COPD Control in High-Risk Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Asthma Control and Adherence with Mepolizumab in Pre-filled Devices for Patients with Asthma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • FEV1: Forced Expiratory Volume in 1 second: The amount of air a person can forcefully exhale in one second. It's a key measure of lung function.
  • FVC: Forced Vital Capacity: The total amount of air exhaled during a forced breath. It's another important measure of lung capacity.
  • AUC: Area Under the Curve: A measurement used to determine the total exposure to a drug over time.
  • pMDI: Pressurized Metered-Dose Inhaler: A device that delivers a specific amount of medication to the lungs in the form of a short burst of aerosolized medicine.
  • COPD: Chronic Obstructive Pulmonary Disease: A group of lung diseases that block airflow and make it difficult to breathe.
  • Bronchodilator: A medication that relaxes the muscles around the airways, making it easier to breathe.
  • Placebo: A substance or treatment with no active therapeutic effect, used as a control in testing new drugs.
  • Bioequivalence: The property of two drugs having the same biological effect in the body.
  • Hyperinflation: A condition where too much air remains in the lungs after exhaling, common in COPD patients.
  • FeNO: Fractional exhaled Nitric Oxide: A biomarker of airway inflammation in asthma.

References

  1. https://clinicaltrials.gov/study/NCT02495168
  2. https://clinicaltrials.gov/study/NCT02533505
  3. https://clinicaltrials.gov/study/NCT00569712
  4. https://clinicaltrials.gov/study/NCT03104634
  5. https://clinicaltrials.gov/study/NCT02384577
  6. https://clinicaltrials.gov/study/NCT05831566
  7. https://clinicaltrials.gov/study/NCT05322707